Atlanta ID Group is committed to our patients’ health and access to the newest treatment options. We are currently participating in the following clinical research drug trials.  If you are interested in being evaluated for one of these clinical research studies, then please discuss with her medical provider.  If you are not a current patient of our practice, then you contact the office at (404) 351-8873 and speak with Steven Schmitt, PA-C, and discuss possible availability of these clinical research studies for you.
(Updated 8 August 2017)

Gilead GS-US-292-0104: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults. Enrollment is currently closed.

Gilead GS-US-292-0111: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricvitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive Antiretroviral Treatment-Naïve Adults. Enrollment is currently closed.

Gilead GS-US-311-1089: A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF. Enrollment is currently closed.

Gilead GS-US-366-1160: A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects. Enrollment is currently closed.

Gilead GS-US-366-1216: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivarine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination Tablet (FDC) is HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivarine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF). Enrollment is currently closed.

Gilead GS-US-311-1717: A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Supressed on Regimens Containing ABC/3TC. Enrollment is currently closed.

Gilead GS-US-380-1489: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. Enrollment is currently closed.